

COVID-19 IgM/IgG Antibody Rapid Test

Assess and protect your workforce with this rapid qualitative screen.

SBL Testing Technologies Inc. ("SBL") provides quality, accurate and reliable COVID-19 IgM/IgG Antibody Test Kits from our well-established manufacturing partners. SBL delivers the antibody tests with comprehensive support, including online test administrator training & certification in multiple languages. SBL also provides a mobile result reporting app to capture and manage test results anywhere in real-time.

A Trusted Partner




- SBL's team has been providing workplace testing solutions for over 15 years
- Well-established manufacturing partners with existing FDA, CE & Health Canada licensed products
- ISO Certified manufacturers
- GMP Facilities
- Isolated to COVID-19 (SARS-CoV-2) antibodies

QUALITY.
ACCURATE.
RELIABLE.

What is Antibody Testing?

This point-of-care lateral flow immunoassay test detects IgM and IgG antibodies against the COVID-19 virus in human blood, detecting patients at different infection stages, typically 5-7 days after symptoms first appear.

- IgM provides the first line of defense during viral infections, followed by the generation of adaptive, high affinity IgG responses for longer-term immunity and immunological memory.
- The detection of IgM antibodies tends to indicate a recent exposure to COVID-19, whereas detection of IgG antibodies indicates a later stage of infection.



Field Ready & Easy to Use

Each box contains:

- 20 test devices
- 20 disposable safety lancets
- 20 10uL whole blood pipettes
- 20 alcohol prep pads
- 1 bottle buffer solution
- 1 instruction sheet



STEP 1: Clean finger



STEP 2: Pierce finger with lancet



STEP 3: Pipette blood sample onto test device



STEP 4: Add buffer, wait 15 minutes, read results

Interpreting Results

Antibody testing is one important component of back-to-work protocols. Antibody testing should be used in conjunction with other risk mitigation measures.

Test Results		Workplace Significance
IgM	IgG	
-	-	Worker has not produced any antibodies and either has no SARS-COV-2 infection or may be in the "incubation period" of SARS-COV-2 infection.
+	-	Worker is actively producing IgM antibodies and may be in the acute phase of SARS-COV-2 infection. The worker should be isolated.
+	+	Worker is actively producing IgM & IgG antibodies and may be in the later phase of SARS-COV-2 infection. The worker should be isolated.
-	+	Worker may have been infected with SARS-COV-2 in the past, but the patient has recovered or the virus in the body has been cleared.





TESTING TECHNOLOGIES

MAKE DECISIONS BASED ON RELIABLE RESULTS

The Support You Need



Online test administrator training & certification, available in multiple languages.



Secure mobile result reporting app captures and manages test results anywhere in real-time.

Clinical Data

IgM TO SARS-CoV-2 DETECTION RESULTS

IgM RESULTS OF CLIA COVID-19 IgM/IgG	IgM RESULTS OF COVID-19 IgM/IgG ANTIBODY TEST		
	PCR +	PCR -	TOTAL
IgM +	74	2	76
IgM -	5	225	230
TOTAL	79	227	306

Relative sensitivity: 93.7% (86.0% - 97.3%)*
Relative specificity: 99.1% (96.8% - 99.8%)*
Overall agreement: 97.7% (95.4% - 98.9%)*
*95% Confidence Interval

IgG TO SARS-CoV-2 DETECTION RESULTS

IgG RESULTS OF CLIA COVID-19 IgM/IgG	IgG RESULTS OF COVID-19 IgM/IgG ANTIBODY TEST		
	PCR +	PCR -	TOTAL
IgG +	82	3	85
IgG -	1	224	225
TOTAL	83	227	306

Relative sensitivity: 98.8% (93.5% - 99.8%)*
Relative specificity: 98.7% (96.2% - 99.5%)*
Overall agreement: 98.7% (96.7% - 99.5%)*
*95% Confidence Interval

Contact Information



SBL Testing Technologies Inc.
2719 7th Ave NE
Suite 112
Calgary, AB T2A 2L9
877-373-8948
sales@sbltt.com
www.sbltt.com



SBL Testing Technologies USA Inc.
1101 South Capital of Texas Hwy
Suite H206
Austin, TX 78745
877-373-8948
sales@sbltt.com
www.sbltt.com